Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Trientin (ausschließlich Darreichungsform FTA), ATC A16AX12 für die Zeit 01.05.26-30.04.28

§ 130a paragraph 8 of the German Social Code Book V (SGB V) allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. In view of the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the German Act Against Restraints of Competition (GWB) is conducted by DAK-Gesundheit. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, with the above-mentioned active substance Trientin (exclusively in the dosage form FTA), ATC A16AX12, DAK-Gesundheit intends to conclude discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new drug discount contracts. A discount contract under the approval model for the above-mentioned active substance will enter into force for the first time on 01.05.2026 and will end on 30.04.2028. It will end automatically with the entry into force of the exclusive contract, regardless.